Cover
Vol. 1 No. 1 (2022)

Published: December 21, 2022

Pages: 6-10

Original Article

Comparison of sitagliptin, glimepiride, and metformin group with glimepiride and metformin group in treatment of diabetes mellitus type 2 patients

Mohammed Fareed Hameed 1 Saba Hameed Majeed 2
1Department of Pharmacology and Toxicology, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
2Department of Clinical Pharmacy, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: October 13, 2022
  • Accepted: November 14, 2022
  • Available Online: December 21, 2022

Abstract

Objective: To compare glycaemia control between glimepiride and metformin group with sitagliptin, glimepiride and metformin group in uncontrolled type 2 diabetic patient. Methods: This retrospective, randomized, clinical study was done in the diabetes research center. The number of the patient in this study was thirty-five patients. The patients examined individually in detail to check their general health in addition to the physical state. For all the patients, data had been collected and fasting plasma glucose level had been measured. Participants have been chosen by unresponsiveness of diabetic patient to single therapy of metformin or glimepiride in this trial. The patients were allocated into 2 groups. Group I include 14 patient given glimepiride, metformin and sitagliptin, while group II include 21 patients given glimepiride and metformin. Both Results: A statistical significant decrease was found in fasting plasma glucose level when compare before and after treatment regimen of sitagliptin, Glimepiride and Metformin group while no significant difference in fasting plasma glucose when comparing the triple therapy group (Sitagliptin, Glimepiride and Metformin) with the double therapy group (Glimepiride and Metformin) after thirty days of treatment. groups continue treatment for thirty days and statistical analyses include data collection was done. Conclusion: No significant difference was found between glimepiride and metformin therapy with sitagliptin, glimepiride and metformin therapy in uncontrolled type 2 diabetic patient.

Keywords

References

  1. Rubin E, Reisner HM. Essentials of Rubin’s Pathology. 6th ed. China: Lippincott Williams & Wilkins; 2014.
  2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21. doi: 10.1016/j.diabres.2011.10.029
  3. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121. doi: 10.1186/s12944-015-0123-1
  4. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5(5):551–9. doi: 10.1097/00075197-200209000-00015
  5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830. doi: 10.1172/JCI19451
  6. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet β-cell failure: A link between type 1 and type 2 diabetes. J Mol Med. 2003;81:455–470. doi: 10.1007/s00109-003-0450-y
  7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0
  8. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81(11):4059–4067. doi: 10.1210/jcem.81.11.8923861
  9. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15(6):755–772. doi: 10.2337/diacare.15.6.755
  10. Galuska D, Zierath J, Thörne A, Sonnenfeld T, Wallberg-Henriksson H. Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle. Diabete Metab. 1991;17(1 Pt 2):159–163.
  11. Ren G, Hou Y, Jiang Y, Li J, Zhang W, Di L, et al. Efficient expression of soluble human FGF-21 and its glucose regulation activity. Yao Xue Xue Bao = Acta Pharmaceutica Sinica. 2009;44(5):548–552.
  12. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(11):820–827. doi: 10.1097/FPC.0b013e3283559b22
  13. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000;49(10 Suppl 2):3–6.
  14. Kabadi UM. Sulfonylurea glimepiride: A proven cost effective, safe and reliable war horse in combating hyperglycemia in type 2 diabetes. JDM. 2015;5(4):211–226. doi: 10.4236/jdm.2015.54026
  15. Dhillon S. Sitagliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489–512. doi: 10.2165/11203790-000000000-00000
  16. Plosker GL. Sitagliptin: A review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(2):223–242. doi: 10.1007/s40265-013-0169-1
  17. Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67(4):587–597. doi: 10.2165/00003495-200767040-00007
  18. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol. 2002;146(5):717–727. doi: 10.1530/eje.0.1460717
  19. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2007;41(1):51–60. doi: 10.1345/aph.1H459
  20. Peacock JL, Peacock PJ. Oxford Handbook of Medical Statistics. 1st ed. China: Oxford University Press; 2011.
  21. Zinman B. Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time? Am J Med. 2011;124(1 Suppl):S19–34. doi: 10.1016/j.amjmed.2010.11.003
  22. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet. 2010;376:103–11. doi: 10.1016/S0140-6736(10)60746-5
  23. Milligan S. Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. J Diabetes Complications. 2016;30:1177–85. doi: 10.1016/j.jdiacomp.2016.03.010
  24. Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017;9(7):667–676. doi: 10.1111/1753-0407.12456
  25. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–745. doi: 10.1111/j.1463-1326.2007.00744.x
  26. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral anti-diabetic drug. Diabetes Obes Metab. 2007;9:153–165. doi: 10.1111/j.1463-1326.2007.00705.x
  27. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55:S20–S27. doi: 10.1016/j.metabol.2006.02.003
  28. Kim G, Oh S, Jin S-M, Hur KY, Kim JH, Lee M-K. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1179–1186. doi: 10.1080/14656566.2017.1353080
  29. Kozawa J, Iwahashi H, Okita K, Okauchi Y, Imagawa A, Shimomura I. Insulin tolerance test predicts the effectiveness of insulin sensitizers in Japanese type 2 diabetic patients. Diabetes Ther. 2010;1:121–130. doi: 10.1007/s13300-010-0011-7
  30. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:1607–1611. doi: 10.2337/diacare.25.9.1607